Skip to main content
Signal8

Karyopharm Announces FDA Acceptance of Supplemental New Drug Application for XPOVIO® (selinexor) Plus Ruxolitinib for the Treatment of Patients with Myelofibrosis

$KPTIQPress releaseNov 17, 2026, 7:30 AM ETRead the release

The FDA accepted Karyopharm's supplemental New Drug Application for XPOVIO (selinexor) plus ruxolitinib in myelofibrosis, with a PDUFA target action date of June 28, 2027. The filing is based primarily on the Phase 3 SENTRY trial (N=353), and if approved the combination could become the first approved therapy for myelofibrosis beyond JAK inhibitors.

Key figures

Drug Name
XPOVIO (selinexor)
Phase Of Trial
Phase 3
Pdufa date
June 28, 2027
Trial name
SENTRY (XPORT-MF-034; NCT04562389)
Trial enrollment
N=353
Chapter11 expected close
Q1 2027
Eu myelofibrosis patients
19000
Us myelofibrosis patients
20000

AI analysis

Red flags3 · Pro

The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.

AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.